Skip to content
Company Analysis

Alterity Therapeutics Limited ATHE

A comprehensive view of key metrics, scores, and financial health for Alterity Therapeutics Limited

Overview of Alterity Therapeutics Limited

ATHE NCM
Healthcare Biotechnology Micro Cap
Alterity Therapeutics Limited (ATHE), is a Micro Cap company, in the Biotechnology industry, last closed at $4.58, about 0.0% overvalued vs fair value, +32.4% 1Y return, ranked 383/1121 in sector.
Metrics ROE -43.2%
$4.58
-0.87%
As of April 28, 2026
Previous close • Vol 90d: 63.3%
52-Week Range
Market Cap
$83.00M
Enterprise Value
$50.00M
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Good
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 44%
Updated: Mar 8
Top Beats

Quick Facts

Website https://alteritytherapeutics.c...
HQ Melbourne, VIC
Employees 9
Fiscal year Jun 30

Next Events

No upcoming events available.

Fair Value Snapshot

Insufficient data
Show more details
  • Revenue data missing or non-positive

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$33.2M
162.4%%
Total Revenue
$0
Net Income
$-12.1M
36.5%%
Operating Expense
$12.3M
-36.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
34.7 months
Excellent

Strong cash position with 2+ years of runway

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Alterity Therapeutics Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
50
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
26
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing ATHE's balance between Growth (34.2%), Profitability (21.6%), and Safety (44.2%). Growth 34% Safety 44% Profitability 22%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

52th percentile vs peers
53
Key Signals
TSR -54.3% 52p
Strengths
  • Cash to Debt Ratio in top 20% of peers (213.30, 94th percentile)
  • Current Ratio in top 20% of peers (12.98, 86th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

68th percentile vs peers
68
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Alterity Therapeutics Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
-
- - -
- upside
-
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info